April 27, 2026 a 06:00 pm

DXCM: Fundamental Ratio Analysis - DexCom, Inc.

DexCom, Inc. stock analysis

DexCom, Inc. operates in the healthcare sector, focusing on continuous glucose monitoring systems. The company's stable product lineup and strategic collaborations position it well for future growth. Recent fundamental ratings reflect a positive, though cautious, investor sentiment.

Fundamental Rating

DexCom has a fundamental rating of B+, indicating a solid financial standing with room for growth in certain areas.

Category Score Visualization
Discounted Cash Flow 4
Return on Equity 5
Return on Assets 5
Debt to Equity 1
Price to Earnings 2
Price to Book 1

Historical Rating

The historical data shows a stable score with slight improvements over time, emphasizing consistent performance in key metrics.

Date Overall Score DCF ROE ROA D/E P/E P/B
- 0 4 5 5 1 2 1
2026-04-27 3 4 5 5 1 2 1

Analyst Price Targets

Analysts forecast a median price target of $86.5, suggesting an upward potential from current levels, with targets ranging between $72 and $95.

High Low Median Consensus
$95 $72 $86.5 $85
DexCom Stock Chart Analysis

Analyst Sentiment

The sentiment among analysts is predominantly positive, with a majority recommending buying the stock.

Recommendation Count Visualization
Strong Buy 1
Buy 41
Hold 8
Sell 2
Strong Sell 0

Conclusion

DexCom, Inc. displays a robust fundamental profile, backed by a sound product lineup and strategic partnerships. While it shows solid return metrics, the debt-to-equity and price valuations suggest areas for improvement. With positive analyst sentiments and price targets indicating potential growth, investors might find DexCom a promising opportunity. However, potential risks remain, notably in competitive pressures and market volatility. Continuous monitoring of its financial health and market position is advisable.